[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-computed-tomography-angiography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-computed-tomography-angiography":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,72,105,145,176,203],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100547647","trustworthy-integrated-artificial-intelligence-tools-for-predicting-high-risk-coronary-plaques-100547647",false,"NCT06410690","Trustworthy, Integrated Artificial Intelligence Tools for Predicting High-risk CORonary PlaqueS","Rustworthy, Integrated Artificial Intelligence Tools for Predicting High-risk CORonary PlaqueS","AI-CORPS","Inclusion Criteria:\n\n* patients (age ≥ 18 years) with known or suspected CAD referred for clinically indicated diagnostic evaluation;\n* CCTA performed with state-of-the-art scanner technology, i.e., scanners with more than 64 slices.\n\nExclusion Criteria:\n\n* performance of any non-invasive diagnostic test within 90 days before enrolment;\n* low-to-intermediate pre-test likelihood of CAD according to the updated Diamond-Forrester risk model score;\n* acute coronary syndrome;\n* evidence of clinical instability;\n* contraindication to contrast agent administration and\u002For impaired renal function;\n* inability to sustain a breath hold;\n* pregnancy;\n* cardiac arrhythmias;- presence of a pacemaker or implantable cardioverter defibrillator;\n* contraindications to the administration of sublingual nitrates, β-blockers or adenosine;\n* structural cardiomyopathy","ALL","18 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","Coronary artery disease (CAD) is among the leading cause of death and disability. Identification of patients at high risk of cardiovascular events is pivotal. However, current risk stratification based on imaging and known biomarkers is suboptimal. The objective of this proposal is to develop a multicriteria decision model for non-invasive assessment of vulnerable atherosclerotic patients and to evaluate its ability to predict the occurrence of an adverse event in intermediate-to-high risk patients with suspected or known CAD. The planned workflow includes a first step using a retrospective cohort of patients undergoing clinically indicated coronary angiography (CCTA) to develop an integrated application for automatic coronary artery segmentation, quantitative plaque analysis, biomechanics and fluid dynamics, based on machine learning, radiomics and computational analysis approaches and validated against the reference standard for each tool. The second step will apply this new methodology to a larger retrospective cohort of patients with the integration of genomic biomarker assessment to derive the most accurate risk stratification model to properly identify vulnerable patients and vulnerable plaques with respect to outcome. Finally, in the third step, the derived predictive model will be prospectively validated in an independent cohort of patients from an ongoing study (CTP-PRO study) to assess the robustness and accuracy of the proposed solution.",[25,26],"Coronary Artery Disease","Coronary Computed Tomography Angiography","RECRUITING","2026-05-26",{"date":30,"type":31},"2026-05-29","ACTUAL",{"date":33,"type":31},"2023-05-22",{"date":35,"type":21},"2026-11-30",{"name":37,"class":38},"Centro Cardiologico Monzino","OTHER",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100637529","computed-tomography-angiography-based-procedural-planning-in-percutaneous-coronary-intervention-100637529","NCT07592312","Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE: Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Ability to provide written informed consent\n* Patients undergoing coronary computed tomography angiography (CCTA) for suspected coronary artery disease or for diagnostic work-up of stabilized acute coronary syndrome\n* Presence of at least one target coronary lesion meeting one of the following CCTA criteria:\n\n  * Severe coronary diameter stenosis (70-99%) in one or more coronary arteries according to CAD-RADS 4A or 4B classification and at least one of the following:\n  * CT-derived fractional flow reserve (CT-FFR) ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n  * Left main coronary artery stenosis ≥50%\n  * Ostial or proximal left anterior descending artery, dominant left circumflex artery, or dominant right coronary artery stenosis ≥50% and at least one of the following:\n  * CT-FFR ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n* Planned clinically indicated invasive coronary angiography with operator decision to proceed with PCI\n\nExclusion Criteria:\n\n* Contraindication to iodinated contrast media, including severe allergy or contrast-induced nephropathy\n* Poor-quality or non-diagnostic CCTA imaging\n* Target lesions involving in-stent restenosis\n* Chronic total occlusion target lesions\n* Operator decision to treat a vessel not identified as a target vessel by the CCTA core laboratory analysis\n* Pregnancy or breastfeeding\n* Patients referred for coronary artery bypass graft surgery after invasive coronary angiography\n* Participation in another investigational drug or drug-coated device study\n* Inability to provide informed consent","80 Years",{"count":50,"type":21},200,"INTERVENTIONAL",[53],"NA","The goal of this clinical trial is to learn whether coronary CT angiography (CCTA)-guided planning improves the efficiency and outcomes of percutaneous coronary intervention (PCI) in adults with coronary artery disease. It will also evaluate the feasibility and safety of using a CT-based \"virtual PCI plan\" during coronary interventions.\n\nThe main questions it aims to answer are:\n\n* Does CCTA-guided PCI reduce procedural time, radiation exposure, and contrast dye use compared with standard PCI?\n* Does CCTA-guided PCI improve procedural outcomes and stent optimization?\n* How often do operators follow or deviate from the CT-based procedural plan?\n* What medical problems or complications occur during and after CCTA-guided PCI?\n\nResearchers will compare CCTA-guided PCI with standard angiography-guided PCI to determine whether CT-derived procedural planning improves PCI efficiency and clinical outcomes.\n\nParticipants will:\n\n* Undergo PCI guided either by a CCTA-based virtual planning strategy or by standard clinical practice\n* Attend follow-up assessments at 1 month, 6 months, and 1 year\n* Undergo routine clinical evaluations and imaging assessments related to their PCI procedure\n* Be monitored for procedural complications, symptoms, repeat procedures, and cardiovascular outcomes during follow-up\n\nThe study will also include a parallel observational registry for patients whose coronary lesions are deferred from PCI, to evaluate their long-term clinical outcomes.",[56,57,58,59,60,26],"Coronary Arteries Disease","Chronic Coronary Syndrome","Acute Coronary Syndromes (ACS)","Myocardial Ischemia","Percutaneous Coronary Intervention",[25,62,60,26],"Chronic Coronary Disease","NOT_YET_RECRUITING","2026-05-13",{"date":66,"type":31},"2026-05-18",{"date":66,"type":21},{"date":69,"type":21},"2028-12-30",{"name":71,"class":38},"University of Galway",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100627362","assessing-the-impact-of-intensification-of-lipid-lowering-therapy-with-guidelines-based-evinacumab-administration-on-coronary-plaque-volumes-measured-by-coronary-computed-tomography-angiography-ccta-in-patients-with-homozygous-familial-hypercholesterolemia-hofh-100627362","NCT07447648","Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)","Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH): A Real World, Prospective and Retrospective, Observational Study","EVOLVE-HoFH","Inclusion Criteria (intensified treatment group - Evinacumab):\n\n1. Willing and able to provide written informed consent form\u002Fassent form for the use of retrospective and prospective data.\n2. Male or female patients aged ≥12 years old at time of enrolment (exception for Italy and France ≥18 years).\n3. Clinical or genetic diagnosis of Homozygous Familial Hypercholesterolemia (HoFH) according to the consensus statement by Cuchel et al, 2023; EHJ (14).\n4. Patients who initiated Evinacumab (at the approved dosage and administration) within 24 months before enrolment as add-on to lipid-lowering treatment (with statins, ezetimibe, PCSK9i and\u002For other agents or treatment) at stable dose for at least 30 days before Evinacumab initiation, as per routine clinical care and no change in dosing is anticipated.\n5. Availability of a baseline CCTA performed at least 6 months prior or 1 month after Evinacumab initiation and a follow-up CCTA performed 18-24 months after Evinacumab initiation.\n6. LDL-cholesterol ≥ 140 mg\u002Fdl (3.5 mmol\u002FL) despite lipid-lowering treatment.\n\nInclusion criteria (conventional treatment group - No Evinacumab)\n\n1. Willing and able to provide written informed consent form\u002Fassent form for the use of retrospective and prospective data.\n2. Male or female patients aged ≥12 years old at time of enrolment (exception for Italy and France ≥18 years).\n3. Clinical or genetic diagnosis of Homozygous Familial Hypercholesterolemia (HoFH) according to the consensus statement by Cuchel et al, 2023; EHJ (14).\n4. Patients with HoFH on standard lipid-lowering therapy (statins, ezetimibe, PCSK9i and\u002For other agents or treatment) at stable dose for at least 30 days before a baseline CCTA and with a follow-up CCTA after 18-24 months from the baseline one.\n\n   * Required lipid lowering therapies: statin, ezetimibe and PCSK9 directed therapy (unless discontinuation due to \\\u003C15% LDL-cholesterol reduction).\n   * Optional additional lipid-lowering therapies:\n   * Lipoprotein apheresis, at stable intervals for at least 3 months.\n   * Lomitapide, at stable dose for at least 3 months.\n5. LDL-cholesterol ≥ 140 mg\u002Fdl (3.5 mmol\u002FL) despite lipid-lowering treatment.\n\nExclusion criteria (intensified treatment group - Evinacumab)\n\n1. Patients participating in a clinical trial with an investigational drug within the last 6 months.\n2. Patients treated outside of Evinacumab approved indication.\n3. Inability to access adequate retrospective clinical data from medical records.\n4. Inability or unwillingness to provide informed consent\u002Fassent or refusal to participate.\n5. Previous multi-vessel coronary artery bypass grafting (CABG). Patients with single-vessel CABG are not excluded.\n6. Pregnancy at the time of the LLT administration.\n7. Moderate to severe renal impairment, or end-stage renal disease (ESRD) undergoing kidney transplantation or chronic renal replacement therapy.\n\nExclusion criteria (conventional treatment group - No Evinacumab)\n\n1. Participation in any interventional clinical trial involving investigational drugs within the last 6 months.\n2. Inability to access adequate retrospective clinical data from medical records.\n3. Inability or unwillingness to provide informed consent\u002Fassent or refusal to participate.\n4. Previous multi-vessel coronary artery bypass grafting (CABG). Patients with single-vessel CABG are not excluded.\n5. Moderate to severe renal impairment, or end-stage renal disease (ESRD) undergoing kidney transplantation or chronic renal replacement therapy.\n6. Pregnancy at the time of the LLT administration.","12 Years",{"count":82,"type":21},52,"This observational, multicenter, retrospective and prospective study aims to evaluate the impact of intensified lipid-lowering therapy including Evinacumab on coronary atherosclerotic plaque burden in patients with Homozygous Familial Hypercholesterolemia (HoFH).\n\nHoFH is a rare genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels from early life and a markedly increased risk of premature atherosclerotic cardiovascular disease. Despite combination lipid-lowering therapy, many patients do not achieve recommended LDL-C targets and remain at high cardiovascular risk.\n\nEvinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), has demonstrated significant LDL-C reduction in clinical trials. However, real-world evidence on its impact on coronary plaque progression is limited.\n\nThe study will compare HoFH patients receiving intensified lipid-lowering therapy including Evinacumab with patients receiving conventional lipid-lowering therapy without Evinacumab. Coronary plaque burden and phenotype will be assessed using coronary computed tomography angiography (CCTA) performed as part of routine clinical practice.\n\nApproximately 52 patients will be enrolled across European centers. The primary objective is to evaluate changes in non-calcified coronary plaque volume between baseline and 18-24 months' follow-up. Secondary objectives include evaluation of total plaque burden, high-risk plaque characteristics, and LDL-C reduction. Exploratory analyses will assess patient-reported outcomes, pericoronary adipose tissue characteristics, and supravalvular atherosclerosis.\n\nAll data are collected from routine clinical care. No additional procedures are mandated by the protocol. This study aims to generate real-world imaging evidence on the effect of intensified lipid-lowering therapy including Evinacumab on coronary atherosclerosis in HoFH.",[85,26],"Homozygous Familial Hypercholesterolemia (HoFH)",[87,88,89,90,91,92,93,94,26],"Evinacumab","Homozygous Familial Hypercholesterolemia","Cardiovascular Disease","LDL Cholesterol","Lipid-Lowering Therapy","Lipid Metabolism Disorders","Atherosclerosis","Rare Genetic Disorders","2026-05-12",{"date":97,"type":31},"2026-05-14",{"date":99,"type":31},"2026-04-30",{"date":101,"type":21},"2029-02",{"name":103,"class":38},"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)",13,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":51,"phases":116,"briefSummary":117,"conditions":118,"keywords":127,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100562453","changes-in-plaque-characteristics-after-short-term-statin-therapy-as-assessed-with-coronary-ct-100562453","NCT06603363","Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","INTENSE","Inclusion Criteria:\n\n* patients referred for coronary computed tomography angiography (CTA)\n* females aged 45-75 years and males aged 40-75 years\n* presence of at least mild coronary atherosclerosis (luminal stenosis \\>25%, with at least one partially calcified or non-calcified plaque)\n* statin-naive patients\n* ability to understand and provide written informed consent\n* FFR-CT value ≥0.75, indicating the absence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* contraindications to coronary CTA\n* current or prior treatment with statins or other lipid-lowering agents (e.g., ezetimibe)\n* age below 45 years in females or below 40 years in males\n* age above 75 years in both sexes\n* pregnancy or breastfeeding\n* type 1 or type 2 diabetes mellitus\n* history of coronary stent implantation or coronary artery bypass grafting\n* history of myocardial infarction\n* ≥70% luminal stenosis in the proximal left anterior descending artery (LAD), or ≥50% stenosis in the left main (LM) coronary artery\n* FFR-CT value \\\u003C0.75 in any coronary artery\n* elevated serum alanine aminotransferase (ALT) levels (\\>3× the upper limit of normal)\n* elevated serum creatine kinase (CK) levels (\\>3× the upper limit of normal)\n* LDL cholesterol level \\>5 mmol\u002FL\n* renal failure or significantly impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* ongoing oncological treatment\n* active liver disease\n* known hypersensitivity to any excipients of the investigational product\n* concomitant treatment with the combination of sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir\n* concomitant treatment with cyclosporine\n* women of childbearing potential not using adequate contraception\n* presence of myopathy","45 Years","75 Years",{"count":115,"type":21},140,[53],"INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to coronary CT angiography due to stable chest pain, followed for 24 months by using a photon-counting detector CT (PCD-CT).\n\nINTENSE Trial aims 1) to assess the effect of short-term intensified statin therapy on coronary anatomy and physiology using PCD-CT and 2) to determine the impact of short-term, intensified statin therapy on coronary plaque morphology and hemodynamics to identify statin responder and non-responder patients in addition to testing the hypothesis of \"plaque memory\" after the 24-month follow-up period.",[25,119,26,120,121,122,123,124,125,126],"Atherosclerotic Plaque","Statin Therapy","Multidetector Computed Tomography","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Vascular Diseases","Hyperlipidemia",[128,129,130,131,132,133,134,135],"coronary artery disease","stable chest pain","intermediate pretest probability","explanatory randomised controlled trial","coronary computed tomography angiography","photon-counting detector CT","atherosclerotic plaque","statin therapy","2026-05-08",{"date":64,"type":31},{"date":139,"type":31},"2025-05-28",{"date":141,"type":21},"2028-12-15",{"name":143,"class":38},"Prof. Maurovich-Horvat Pál",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":51,"phases":155,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":144},"100567636","myocardial-perfusion-quantification-with-spect-using-multi-pinhole-collimator-compared-to-photon-counting-coronary-cta-100567636","NCT06670768","Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA","Myocardial Perfusion Quantification With Single Photon Emission Computed Tomography Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary Computed Tomography Angiography","MY-FUSION","Inclusion Criteria:\n\n* suspected coronary artery disease\n* referred to coronary CTA or SPECT MPI by the patient's physician\n* agrees to the other imaging modality that was not indicated by their physician (coronary CTA or SPECT MPI)\n* suitable for informed consent\n\nExclusion Criteria:\n\n* moderate or severe aortic valve stenosis\n* atrial fibrillation\n* pregnancy or breastfeeding\n* history of coronary artery bypass graft implantation\n* history of stent implantation\n* chronic renal failure (eGFR \\\u003C 30 ml\u002Fm2)\n* active oncological treatment\n* congenital heart disease\n* left or right bundle branch block",{"count":154,"type":21},50,[53],"This prospective study aims to compare functional abnormalities detected using myocardial perfusion SPECT imaging (MPI SPECT) with the extent and severity of anatomical findings on coronary computed tomography angiography (coronary CTA). Additionally, the investigators aim to enhance the diagnostic value of MPI SPECT by quantifying myocardial blood flow and utilizing myocardial flow reserve calculated from dynamic SPECT images.\n\n50 patients with suspected coronary artery disease are anticipated to be enrolled. Pharmacological stress and rest-phase dynamic and static MPI SPECT following an additional coronary CTA scan are to be performed. The obtained multimodality imaging data (functional and anatomical parameters) are planned to be compared and subjected to statistical analysis. The results of this study are expected to improve risk assessment for patients with moderate cardiovascular risk and enhance the diagnostic performance of MPI SPECT.",[25,26,158,122,123,124,59,159,160],"SPECT","Coronary Disease","Chest Pain",[162,163,164,165,166],"Coronary Artery Disease,","Myocardial Perfusion Imaging","Myocardial Perfusion Imaging Absolute Quantification","Myocardial Flow Reserve","Plaque volume","2025-04-24",{"date":169,"type":31},"2025-04-25",{"date":171,"type":31},"2024-03-06",{"date":173,"type":21},"2026-08-30",{"name":175,"class":38},"Semmelweis University",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":51,"phases":184,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":144},"100583703","optimization-of-patient-preparation-and-imaging-techniques-for-cardiac-ct-100583703","NCT06879769","Optimization of Patient Preparation and Imaging Techniques for Cardiac CT","Inclusion Criteria:\n\n* Participant with a preexisting referral for a Cardiac CT examination\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Age under 18 years\n* Atrial fibrillation\n* Pacemaker\n* Participation in clinical drug trials\n* Contraindications to beta-blockers\n* Severe medical conditions\n* Challenges in comprehending study information\n* Pregnancy",{"count":183,"type":21},240,[53],"The goal of this clinical trial is to compare four different methods of reducing heart rate before cardiac imaging. The diagnostic imaging technique used in this study is called Computed Tomography (CT) of the coronary vessels (CCTA). Globally, approximately one-third of patients experience heart-related conditions. Because the heart is a moving organ, imaging presents challenges. A higher heart rate requires increased scanning power, which results in more images and, in some cases, higher radiation exposure that may be harmful. To address this issue, beta-blocker medication is administered before the examination to lower the heart rate. This medication can be given orally, intravenously, or both. While this approach is effective, the most optimal method remains uncertain.\n\nThe objectives of this study are:\n\n* To determine whether oral administration of beta-blockers is as effective as intravenous administration in maintaining a stable heart rate during CT imaging.\n* To assess whether listening to music during the procedure improves patient comfort and overall experience.\n\nParticipants will:\n\n* Be randomly assigned to one of four groups:\n* One group will receive beta-blocker medication orally.\n* Another group will receive beta-blocker medication intravenously.\n* One group will listen to music during the procedure. Participants will report their sensations and experiences before, during, and after the examination.\n\nThe study investigators will compare the effectiveness of oral and intravenous beta-blockers, as well as the impact of music, in terms of:\n\n* Heart rate stability and reduction.\n* Participant-reported comfort and overall experience.",[26,187,188],"Contrast Media","Cardiac Output",[190,188,191,192,193],"Music intervention","CCTA","Beta blockers","Metoprolol","2025-03-14",{"date":196,"type":31},"2025-03-17",{"date":198,"type":31},"2021-01-01",{"date":200,"type":21},"2027-12-01",{"name":202,"class":38},"Karolinska University Hospital",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":213,"studyType":22,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100415546","ccta-improves-clinical-management-of-stable-chest-pain-100415546","NCT04691037","CCTA Improves Clinical Management of Stable Chest Pain","Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Computed Tomography Coronary Angiography","CICM-SCP","Inclusion Criteria:\n\n* symptomatic patients with SCP suspected of obstructive CAD.\n* referred for CCTA for the assessment of SCP.\n* ≥18 years of age.\n* signed informed consent.\n\nExclusion Criteria:\n\n* acute coronary syndromes\n* previous CAD or coronary revascularization\n* nonsinus rhythm\n* cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons",{"count":212,"type":21},50000,"3 Years","The investigator aims to prospectively enroll patients who were referred for coronary computed tomography angiography (CCTA) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary. This study will determine if CCTA-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.",[26,216,217,218,219,220,25],"Stable Chest Pain","Optimal Medical Therapy","Invasive Coronary Angiography","Revascularization","Major Adverse Cardiovascular Events","2024-03-26",{"date":223,"type":31},"2024-03-28",{"date":225,"type":31},"2016-01-01",{"date":227,"type":21},"2030-01-01",{"name":229,"class":38},"Tianjin Chest Hospital",4]